Jump to:
Aptamer Group PLC Fundamentals
| Company Name | Aptamer Group PLC | Last Updated | 2024-05-02 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 467.344 m | Market Cap | £3.15 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.11 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.2661 | Debt Equity Ratio | 0.3236 |
|---|
| Asset Equity Ratio | 1.9940 | Cash Equity Ratio | 0.8824 |
|---|
| Quick Ratio | 1.4675 | Current Ratio | 2.14 |
|---|
| Price To Book Value | 1.5853 | ROCE | 0 |
|---|
Aptamer Group PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Aptamer Group PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £721,000.00 | £1.82 m | £519,000.00 |
| Intangible Assets | £70,000.00 | £341,000.00 | £222,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £1.16 m | £2.54 m | £741,000.00 |
| Stocks | £204,000.00 | £420,000.00 | £90,000.00 |
| Debtors | £501,000.00 | £1.15 m | £266,000.00 |
| Cash & Equivalents | £234,000.00 | £6.69 m | £369,000.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £2.75 m | £11.52 m | £2.06 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £1.64 m | £2.37 m | £1.86 m |
| Creditors after 1 year | £806,000.00 | £1.09 m | £94,000.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £2.45 m | £3.47 m | £1.96 m |
| Net assets | £304,000.00 | £8.05 m | £105,000.00 |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £69,000.00 | £69,000.00 | £30,000.00 |
| Share Premium | £9.58 m | £9.57 m | £5.20 m |
| Profit / Loss | -£8.30 m | -£2.64 m | -£2.91 m |
| Other Equity | £304,000.00 | £8.05 m | £105,000.00 |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £304,000.00 | £8.05 m | £105,000.00 |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | £0.72 | £0.12 | 0 |
| Debt-to-Equity | £2.51 | £0.13 | 0 |
| Assets / Equity | 1.9940 | 1.9940 | 1.9940 |
| Cash / Equity | 0.8824 | 0.8824 | 0.8824 |
| EPS | -£0.11 | -£0.03 | -£0.03 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£4.06 m | -£2.38 m | -£1.37 m |
| Cashflow before financing | -£4.43 m | £6.74 m | £500,000.00 |
| Increase in Cash | -£6.46 m | £6.32 m | £76,000.00 |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | £1.75 m | £4.04 m | £1.60 m |
| Cost of sales | £1.39 m | £1.35 m | £927,000.00 |
| Gross Profit | £359,000.00 | £2.69 m | £673,000.00 |
| Operating Profit | -£8.16 m | -£2.58 m | -£2.87 m |
| Pre-Tax profit | -£8.30 m | -£2.64 m | -£2.91 m |
Aptamer Group PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. |
|---|
| Latest Interim Date | 28 Mar 2024 |
|---|
| Latest Fiscal Year End Date | 9 Nov 2023 |
|---|
Aptamer Group PLC Directors
| Appointed | Name | Position |
|---|
| 2023-10-09 | Mr. Stephen Hull | Executive Director,Chairman |
| 2023-11-21 | Dr. Ian David Gilham | Executive Director,Chairman |
| 2023-10-09 | Mr. Dean Andrew Fielding | Non-Executive Director |
| 2023-11-20 | Dr. Arron Craig Tolley | Executive Director,Chief Technology Officer |
| 2023-10-09 | Dr. David Harry John Bunka | Executive Director,Chief Scientific Officer |
| 2022-06-13 | Ms. Eleanor Margaret Brown | Executive Director,Chief Financial Officer and Company Secretary |
| 2023-10-09 | Dr. Adam Hargreaves | Non-Executive Director |
Aptamer Group PLC Contact Details
Aptamer Group PLC Advisors
